Health

August 30, 2017 - 3:47 pm
COLUMBUS, Ohio (AP) — Ohio says a record 4,050 people died of drug overdoses in the state last year, driven in large part by the emergence of stronger drugs like the synthetic painkiller fentanyl. The data released Wednesday mean on average, 11 Ohioans are dying each day by overdosing on pain pills...
Read More
August 30, 2017 - 3:47 pm
COLUMBUS, Ohio (AP) — Ohio says a record 4,050 people died of drug overdoses in the state last year, driven in large part by the emergence of stronger drugs like the synthetic painkiller fentanyl. The data released Wednesday mean on average, 11 Ohioans are dying each day by overdosing on pain pills...
Read More
August 30, 2017 - 3:47 pm
COLUMBUS, Ohio (AP) — Ohio says a record 4,050 people died of drug overdoses in the state last year, driven in large part by the emergence of stronger drugs like the synthetic painkiller fentanyl. The data released Wednesday mean on average, 11 Ohioans are dying each day by overdosing on pain pills...
Read More
This photo provided by the Children’s Hospital of Philadelphia, taken in May 2017, shows Emily Whitehead five years after she became the first pediatric patient in the world to receive an experimental therapy at the hospital that has put her leukemia into long-term remission. Opening a new era in cancer care, the Food and Drug Administration (FDA) approved the first treatment that genetically engineers patients' own blood cells into an army of assassins to seek and destroy childhood leukemia. (Children’s Hospital of Philadelphia via AP)
August 30, 2017 - 12:44 pm
WASHINGTON (AP) — Opening a new era in cancer care, the Food and Drug Administration on Wednesday approved the first treatment that genetically engineers patients' own blood cells into an army of assassins to seek and destroy childhood leukemia. The CAR-T cell treatment developed by Novartis...
Read More
This photo provided by the Children’s Hospital of Philadelphia, taken in May 2017, shows Emily Whitehead five years after she became the first pediatric patient in the world to receive an experimental therapy at the hospital that has put her leukemia into long-term remission. Opening a new era in cancer care, the Food and Drug Administration (FDA) approved the first treatment that genetically engineers patients' own blood cells into an army of assassins to seek and destroy childhood leukemia. (Children’s Hospital of Philadelphia via AP)
August 30, 2017 - 12:44 pm
WASHINGTON (AP) — Opening a new era in cancer care, the Food and Drug Administration on Wednesday approved the first treatment that genetically engineers patients' own blood cells into an army of assassins to seek and destroy childhood leukemia. The CAR-T cell treatment developed by Novartis...
Read More
This photo provided by the Children’s Hospital of Philadelphia, taken in May 2017, shows Emily Whitehead five years after she became the first pediatric patient in the world to receive an experimental therapy at the hospital that has put her leukemia into long-term remission. Opening a new era in cancer care, the Food and Drug Administration (FDA) approved the first treatment that genetically engineers patients' own blood cells into an army of assassins to seek and destroy childhood leukemia. (Children’s Hospital of Philadelphia via AP)
August 30, 2017 - 12:44 pm
WASHINGTON (AP) — Opening a new era in cancer care, the Food and Drug Administration on Wednesday approved the first treatment that genetically engineers patients' own blood cells into an army of assassins to seek and destroy childhood leukemia. The CAR-T cell treatment developed by Novartis...
Read More
This photo provided by the Children’s Hospital of Philadelphia, taken in May 2017, shows Emily Whitehead five years after she became the first pediatric patient in the world to receive an experimental therapy at the hospital that has put her leukemia into long-term remission. Opening a new era in cancer care, the Food and Drug Administration (FDA) approved the first treatment that genetically engineers patients' own blood cells into an army of assassins to seek and destroy childhood leukemia. (Children’s Hospital of Philadelphia via AP)
August 30, 2017 - 12:44 pm
WASHINGTON (AP) — Opening a new era in cancer care, the Food and Drug Administration on Wednesday approved the first treatment that genetically engineers patients' own blood cells into an army of assassins to seek and destroy childhood leukemia. The CAR-T cell treatment developed by Novartis...
Read More
This photo provided by the Children’s Hospital of Philadelphia, taken in May 2017, shows Emily Whitehead five years after she became the first pediatric patient in the world to receive an experimental therapy at the hospital that has put her leukemia into long-term remission. Opening a new era in cancer care, the Food and Drug Administration (FDA) approved the first treatment that genetically engineers patients' own blood cells into an army of assassins to seek and destroy childhood leukemia. (Children’s Hospital of Philadelphia via AP)
August 30, 2017 - 11:57 am
WASHINGTON (AP) — Opening a new era in cancer care, the Food and Drug Administration on Wednesday approved the first treatment that genetically engineers patients' own blood cells into an army of assassins to seek and destroy childhood leukemia. The CAR-T cell treatment developed by Novartis and...
Read More
August 30, 2017 - 11:27 am
WASHINGTON (AP) — Opening a new era in cancer care, the Food and Drug Administration on Wednesday approved the first treatment that genetically engineers patients' own blood cells into an army of assassins to seek and destroy childhood leukemia. The CAR-T cell treatment developed by Novartis and...
Read More
August 30, 2017 - 11:27 am
WASHINGTON (AP) — Opening a new era in cancer care, the Food and Drug Administration on Wednesday approved the first treatment that genetically engineers patients' own blood cells into an army of assassins to seek and destroy childhood leukemia. The CAR-T cell treatment developed by Novartis and...
Read More

Pages